JP2009502796A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502796A5
JP2009502796A5 JP2008522900A JP2008522900A JP2009502796A5 JP 2009502796 A5 JP2009502796 A5 JP 2009502796A5 JP 2008522900 A JP2008522900 A JP 2008522900A JP 2008522900 A JP2008522900 A JP 2008522900A JP 2009502796 A5 JP2009502796 A5 JP 2009502796A5
Authority
JP
Japan
Prior art keywords
methyl
acid
ylamino
imidazol
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522900A
Other languages
English (en)
Other versions
JP5129132B2 (ja
JP2009502796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/027878 external-priority patent/WO2007015871A1/en
Publication of JP2009502796A publication Critical patent/JP2009502796A/ja
Publication of JP2009502796A5 publication Critical patent/JP2009502796A5/ja
Application granted granted Critical
Publication of JP5129132B2 publication Critical patent/JP5129132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (7)

  1. 4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミドの塩。
  2. 塩酸塩、塩酸塩一水和物、一リン酸塩、二リン酸塩、硫酸塩、メタンスルホン酸塩、エタンスルホン酸塩、ベンゼンスルホン酸塩およびp−トルエンスルホン酸塩から成る群から選択される、請求項1に記載の塩
  3. 4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミドの塩の製造方法であって、4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミド遊離塩基と、酸を溶媒中で反応させる工程を含む、方法。
  4. 酸が塩酸、リン酸、硫酸、スルホン酸、メタンスルホン酸、エタンスルホン酸、ベンゼンスルホン酸、p−トルエンスルホン酸、クエン酸、フマル酸、ゲンチシン酸、マロン酸、マレイン酸および酒石酸から成る群から選択される、請求項3に記載の方法。
  5. 4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミド一塩酸塩一水和物の製造方法であって:
    (a)4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミド遊離塩基および塩酸をメタノール中、窒素雰囲気下で合わせ;
    (b)反応混合物を42−50℃の温度範囲に加熱し;
    (c)反応混合物を撹拌し;
    (d)反応混合物を40℃以上の温度を維持しながら濾過して透明溶液を得て;
    (e)透明溶液を窒素雰囲気下で撹拌しながら30℃に冷却し;
    (f)溶液に種晶添加し;
    (g)種晶添加した溶液を23℃に冷却し;
    (h)溶液を撹拌して懸濁液を得て;
    (i)懸濁液を−10℃に冷却し;
    (j)懸濁液を撹拌し;
    (k)固体を濾過し;
    (l)固体を冷メタノールで濯ぎ;そして
    (m)固体を50−55℃および10−20torrで乾燥させて、4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミド一塩酸塩一水和物を得る
    工程を含む、方法。
  6. (a)治療的有効量の請求項1または2のいずれかに記載の塩;および
    (b)少なくとも1種の薬学的に許容される担体、希釈剤、媒体または賦形剤
    を含む、医薬組成物。
  7. 塩が4−メチル−N−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミド一塩酸塩一水和物である、請求項6に記載の医薬組成物。
JP2008522900A 2005-07-20 2006-07-18 4−メチル−n−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミドの塩 Active JP5129132B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US60/701,406 2005-07-20
US71621305P 2005-09-12 2005-09-12
US60/716,213 2005-09-12
PCT/US2006/027878 WO2007015871A1 (en) 2005-07-20 2006-07-18 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (3)

Publication Number Publication Date
JP2009502796A JP2009502796A (ja) 2009-01-29
JP2009502796A5 true JP2009502796A5 (ja) 2009-09-03
JP5129132B2 JP5129132B2 (ja) 2013-01-23

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522900A Active JP5129132B2 (ja) 2005-07-20 2006-07-18 4−メチル−n−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミドの塩

Country Status (34)

Country Link
US (4) US8163904B2 (ja)
EP (2) EP2186808B1 (ja)
JP (1) JP5129132B2 (ja)
KR (3) KR101755137B1 (ja)
CN (1) CN102267981A (ja)
AR (1) AR057467A1 (ja)
AT (1) ATE514689T1 (ja)
AU (2) AU2006276205B2 (ja)
BR (1) BRPI0613605A2 (ja)
CA (2) CA2823946C (ja)
CY (1) CY1111772T1 (ja)
DK (1) DK1910336T3 (ja)
EC (1) ECSP088118A (ja)
ES (1) ES2634291T3 (ja)
GT (1) GT200600316A (ja)
HK (1) HK1116778A1 (ja)
HR (1) HRP20110639T1 (ja)
IL (1) IL187787A (ja)
JO (1) JO2757B1 (ja)
MA (1) MA29686B1 (ja)
MX (1) MX2008000892A (ja)
MY (1) MY149889A (ja)
NO (1) NO341313B1 (ja)
NZ (2) NZ591142A (ja)
PE (1) PE20070241A1 (ja)
PL (1) PL1910336T3 (ja)
PT (1) PT1910336E (ja)
RU (4) RU2509767C1 (ja)
SG (1) SG170772A1 (ja)
SI (1) SI1910336T1 (ja)
TN (1) TNSN08028A1 (ja)
TW (1) TWI455934B (ja)
UY (1) UY29683A1 (ja)
WO (1) WO2007015871A1 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
US20100152198A1 (en) * 2006-04-07 2010-06-17 Manley Paul W Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2305667A3 (en) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
JP5486012B2 (ja) 2008-11-05 2014-05-07 テバ ファーマシューティカル インダストリーズ リミティド ニロチニブHCl結晶形
EP2186514B1 (en) * 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
CA2753637A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
EP2490690A1 (en) 2009-10-23 2012-08-29 Novartis AG Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (ja) 2010-01-15 2016-09-02
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
KR20130042498A (ko) * 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
WO2012014127A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
EP2648519A4 (en) * 2010-11-26 2014-04-30 Hetero Research Foundation NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
KR20140096035A (ko) 2011-10-28 2014-08-04 노파르티스 아게 위장 기질 종양을 치료하는 방법
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP6275645B2 (ja) 2011-11-14 2018-02-07 ノバルティス アーゲー 4−メチル−3−[[4−(3−ピリジニル)−2−ピリミジニル]アミノ]−n−[5−(4−メチル−1h−イミダゾール−1−イル)−3−(トリフルオロメチル)フェニル]ベンズアミドの即放性製剤
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
WO2014059518A1 (en) * 2012-10-15 2014-04-24 Apotex Technologies Inc. Solid forms of nilotinib hydrochloride
MX2015004947A (es) * 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
JP2016522182A (ja) * 2013-04-24 2016-07-28 ドクター レディズ ラボラトリーズ リミテッド ニロチニブ塩酸塩の多形形態
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
LT3189045T (lt) * 2014-08-11 2022-04-11 Sun Pharmaceutical Industries Limited Naujos nilotinibo druskos ir jų polimorfai
US10301282B2 (en) 2015-03-20 2019-05-28 Cipla Limited Polymorphic form X of nilotinib dihydrochloride hydrate
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
PL3430004T3 (pl) 2016-03-14 2021-01-25 Pliva Hrvatska D.O.O. Postaci soli nilotynibu w stanie stałym
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US20230075170A1 (en) 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PL179417B1 (en) 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE60034963D1 (de) * 1999-12-14 2007-07-05 Nippon Shinyaku Co Ltd Heterocyclische derivate und arzneistoffe
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Similar Documents

Publication Publication Date Title
JP2009502796A5 (ja)
JP5129132B2 (ja) 4−メチル−n−[3−(4−メチル−イミダゾル−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミドの塩
EP1803709B1 (en) Proton pump inhibitors
CN105884781B (zh) 一种枸橼酸托法替布的制备方法
EP1919865B1 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
EP3613734B1 (en) Process for producing pyrrole compound
KR100803796B1 (ko) 세로토닌 및 노르아드레날린 재흡수 억제제로서의n-피롤리딘-3-일-아미드 유도체
TWI406661B (zh) 4-甲基-n-〔3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基〕-3-(4-吡啶-3-基-嘧啶-2基胺基)-苯甲醯胺之結晶型
EP2114917B1 (en) Pyrrole compounds
EP1874778B1 (en) Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
EP1787991B1 (en) PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
TW200848043A (en) Substituted isoquinoline and isoquinolinone derivatives
JP2019506379A (ja) ルキソリチニブの合成プロセス
US20100004293A1 (en) Crystalline forms of aryl-substituted pyrazole-amide compounds
EP3689861B1 (en) Optically active pyrrolidine compound and method for producing same
AU2015268744B2 (en) 1-Heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
WO2015157360A1 (en) Processes to make protein kinase inhibitors
UA80338C2 (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors, processes for their preparation, pharmaceutical composition containing them
ITBO950569A1 (it) Forma polimorfa di terazosin monocloridrato e processo per la sua produzione.